DEFA14A: Bluebird Bio Adjourns Stockholders Meeting, Seeks Approval for Reverse Stock Split Amid Nasdaq Delisting Concerns

Bluebird Bio adjourned its annual meeting to solicit additional votes for a reverse stock split proposal aimed at maintaining Nasdaq listing and securing future financing.

Summary

• Bluebird Bio adjourned its annual meeting of stockholders on November 6, 2024, to gather more votes for Proposal 4, which involves a reverse stock split.
• The company's stockholders approved Proposals 1, 2, 5, 6, and 7, but did not approve Proposal 3.
• The meeting will reconvene on December 4, 2024, to focus solely on Proposal 4.
• Proposal 4 aims to amend the company's charter to allow a reverse stock split at a ratio between 1-for-15 and 1-for-20.
• The reverse stock split is intended to help Bluebird Bio maintain its Nasdaq listing and provide flexibility in securing financing.
• The company needs more than 50% of total shares outstanding to approve the reverse stock split.
• Independent proxy advisory firms ISS and Glass Lewis have recommended voting in favor of the reverse stock split.
• Bluebird Bio will host a conference call on November 14, 2024, to discuss third-quarter 2024 results and business updates.
• The company is pursuing curative gene therapies and has secured FDA approvals for three therapies in under two years.
• Bluebird Bio faces risks related to commercialization, manufacturing, funding, and regulatory compliance.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative due to the risk of Nasdaq delisting and the need for a reverse stock split, although the company has positive aspects such as FDA approvals and support from proxy advisory firms. The need for additional capital and the uncertainty around future financing contribute to the lower score.

Positives

• Bluebird Bio has secured FDA approvals for three gene therapies.
• Independent proxy advisory firms recommend voting for the reverse stock split.
• The company is pursuing multiple sources of capital to reach cash flow breakeven.
• Stockholder votes are in favor of Proposal 4 by approximately two to one.

Negatives

• Bluebird Bio is at risk of being delisted from Nasdaq.
• The company needs further capital to reach its expected cash flow breakeven point.
• Approval for the proposed reverse stock split requires a vote of more than 50 percent of the total shares outstanding.
• The company is soliciting stockholders for additional votes to approve Proposal 4.

Risks

• Delays and challenges in commercialization and manufacturing of products.
• Higher than expected internal and external costs impacting cash usage.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Risk that additional funding may not be available on acceptable terms.
• Risks related to the loan agreement, including operating restrictions and compliance with covenants.
• Risk of insertional oncogenic or other safety events associated with lentiviral vector, drug product, or myeloablation.
• Risks related to compliance with Nasdaq continued listing requirements.

Future Outlook

Bluebird Bio aims to reach cash flow breakeven in the second half of 2025 and is pursuing multiple financing options. The company's future depends on stockholder approval of Proposal 4 and successful commercialization of its gene therapies.

Management Comments

• Andrew Obenshain, CEO, stated that the reverse stock split is intended to support efforts to restore stockholder value and provide flexibility as the Company considers financing options.
• Andrew Obenshain, CEO, mentioned that further capital is required to reach their expected cash flow breakeven point in the second half of next year.

Industry Context

Bluebird Bio's focus on gene therapies aligns with the growing interest in innovative treatments for severe genetic diseases. The company's challenges in maintaining its Nasdaq listing and securing financing reflect the difficulties faced by many biotech companies in the current market environment.

Comparison to Industry Standards

• Other gene therapy companies, such as CRISPR Therapeutics and Vertex Pharmaceuticals, are also focused on developing treatments for genetic diseases.
• Many biotech companies face challenges in securing funding and achieving profitability, especially during the early stages of commercialization.
• Reverse stock splits are a common strategy for companies facing delisting from major stock exchanges, but their success depends on the company's ability to improve its financial performance and investor confidence.

Stakeholder Impact

• Shareholders face potential dilution from the reverse stock split and uncertainty regarding the company's future performance.
• Employees may be affected by potential cost-cutting measures or changes in the company's strategic direction.
• Patients could benefit from the continued development and commercialization of gene therapies, but may also face risks related to access and affordability.
• Creditors face risks related to the company's ability to repay its debts and comply with loan covenants.

Next Steps

• Soliciting stockholders for additional votes to approve Proposal 4.
• Reconvening the Annual Meeting on December 4, 2024.
• Hosting a conference call on November 14, 2024, to discuss third quarter 2024 results.
• Pursuing multiple sources of capital to reach cash flow breakeven.

Key Dates

Keywords

reverse stock split, bluebird bio, Nasdaq delisting, annual meeting, gene therapy, financing, stockholders, proposal 4